New Covid drug Sotrovimab that cuts risk of death by nearly 80% is approved in UK

A NEW Covid drug that cuts the risk of death by nearly 80 per cent has been APPROVED in the UK.

Sotrovimab has been given the green light as it’s been deemed safe and effective at reducing the risk of hospitalisation and death in Covid patients.

GettySotrovimab has been given the green light[/caption]

The antibody treatment is most effective during the early stages of coronavirus illness.

And clinical trials showed that the drug was able to reduce the risk of hospitalisation and death by 79 per cent among high-risk adults.

The regulator said this morning: “In a clinical trial, a single dose of the monoclonal antibody was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection.

“Based on the clinical trial data, sotrovimab is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible and within five days of symptom onset.”

More to follow…

For the latest news on this story keep checking back at Sun Online.

Thesun.co.uk is your go to destination for the best celebrity news, football news, real-life stories, jaw-dropping pictures and must-see video.

Download our fantastic, new and improved free App for the best ever Sun Online experience. For iPhone click here, for Android click here. 

Like us on Facebook at www.facebook.com/thesun and follow us from our main Twitter account at @TheSun.